Bolt Biotherapeutics
Jakob Dupont, MD MA, is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as a Member of the Board of Directors at Bolt Biotherapeutics, Avenzo Therapeutics, and Pyxis Oncology, while also holding the position of Executive Partner at Sofinnova Investments. With extensive experience in research and development, Dupont has been a consultant at Atara Biotherapeutics and Gossamer Bio, and played a key role in the historic approval of EBVallo, the first allogeneic T cell therapy. Educational credentials include a Doctor of Medicine from Joan & Sanford I. Weill Medical College of Cornell University, a Master of Arts in Philosophy from New York University, and a Bachelor of Arts in Philosophy from Vassar College.
This person is not in the org chart
This person is not in any teams
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.